Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results

14 Aug 2026, 19:56 by Teresa Graham · The Cerbat Gem

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.05), FiscalAI reports.

Galectin Therapeutics Stock Performance

NASDAQ GALT traded down $0.09 during mid-day trading on Friday, reaching $3.44. 388,201 shares of the stock were exchanged, compared to its average volume of 470,796. The company has a market capitalization of $226.56 million, a P/E ratio of -8.39 and a beta of 0.41. The business’s 50 day moving average is $3.58 and its 200-day moving average is $2.99. Galectin Therapeutics has a 1 year low of $2.03 and a 1 year high of $7.13.

Wall Street Analysts Forecast Growth

GALT has been the subject of a number of recent analyst reports. Wall Street Zen raised Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Zacks Research upgraded Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, June 23rd. Finally, Weiss Ratings upgraded shares of Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Galectin Therapeutics has a consensus rating of “Hold” and an average target price of $11.00.

View Our Latest Research Report on Galectin Therapeutics

Insider Buying and Selling

In other news, insider Khurram Jamil sold 47,467 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.04, for a total transaction of $239,233.68. Following the transaction, the insider owned 2,037 shares in the company, valued at $10,266.48. This trade represents a 95.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Harold H. Shlevin sold 22,268 shares of Galectin Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total value of $112,230.72. Following the completion of the sale, the director owned 6,500 shares in the company, valued at approximately $32,760. The trade was a 77.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 90,162 shares of company stock worth $438,464 in the last quarter. Insiders own 52.60% of the company’s stock.

Institutional Trading of Galectin Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in Galectin Therapeutics by 25.4% in the third quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after purchasing an additional 3,133 shares during the period. Royal Bank of Canada grew its position in shares of Galectin Therapeutics by 1,197.3% during the fourth quarter. Royal Bank of Canada now owns 6,175 shares of the company’s stock worth $25,000 after buying an additional 5,699 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of Galectin Therapeutics during the fourth quarter worth approximately $43,000. State Street Corp increased its stake in shares of Galectin Therapeutics by 5.2% during the fourth quarter. State Street Corp now owns 242,232 shares of the company’s stock worth $1,008,000 after buying an additional 11,892 shares during the period. Finally, Cetera Investment Advisers acquired a new stake in Galectin Therapeutics in the fourth quarter valued at approximately $59,000. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.